ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1148

Interstitial Lung Disease in MCTD: A Retrospective Cohort Study at a Large Tertiary Medical Center

Alana Haussmann1 and Elizabeth Volkmann2, 1University of California Los Angeles, Los Angeles, CA, 2Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA

Meeting: ACR Convergence 2025

Keywords: Cohort Study, interstitial lung disease, Miscellaneous Rheumatic and Inflammatory Diseases, population studies, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Mixed connective tissue disease (MCTD) is a rare autoimmune condition defined by the presence of anti-U1-ribonucleoprotein (RNP) antibodies and clinical features of at least two other connective tissue diseases (CTDs). Pulmonary complications, including interstitial lung disease (ILD), are the leading causes of morbidity and mortality in this population. The clinical phenotype, natural history, and risk factors for ILD in MCTD remain poorly characterized. This study aims to evaluate the prevalence of MCTD and characterize clinical differences between MCTD patients with and without ILD.

Methods: We conducted a retrospective review of patients seen within the UCLA Health System between April 1, 2005, and April 1, 2025. Eligible patients had a CTD ICD-10 code of either M35.1 or M35.9, were at least 18 years of age, and had a positive anti-U1-RNP antibody. Individuals with a medical history of systemic sclerosis, rheumatoid arthritis, systemic lupus erythematosus, or inflammatory myositis were excluded. Patients with ILD were identified based on diagnosis documentation in the electronic medical record. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess differences in clinical and demographic characteristics between MCTD patients with and without ILD.

Results: A total of 581 patients with MCTD were included in the study. The majority were female (86.9%) with a mean age of 50 years (range: 18–96) (Table 1). The cohort was racially diverse, with 35.3% identifying as Caucasian, 18.4% as Black/African American, and 15.7% as Asian/Pacific Islander. ILD was present in 120 patients (20.7%). Patients with and without ILD did not differ significantly in terms of sex, body mass index (BMI), race, or smoking status. However, patients with MCTD and ILD were significantly more likely to be over the age of 55 (OR 2.50; 95% Cl: 1.62–3.86), ethnically Hispanic (OR 2.21; 95% CI 1.40-3.49), report dysphagia (OR 3.03; 95% CI: 1.85–4.95), and have documented diagnoses of gastroesophageal reflux disease (GERD) (OR 3.66; 95% CI: 2.37–5.70), as well as pulmonary hypertension (PH) (OR 7.13; 95% CI: 4.24–12.10).

Conclusion: This study represents the largest evaluation of patients with MCTD and underscores the notable burden of ILD in this population. Universal screening for ILD in MCTD remains controversial. The present study sheds light on the distinguishing clinical features of patients with MCTD-ILD (e.g., older age, Hispanic, GERD, dysphagia, PH) that if present, could prompt evaluation for ILD and lead to earlier diagnosis.

Supporting image 1Table 1. Characteristics of patients with MCTD with and without ILD (N&#3f581)


Disclosures: A. Haussmann: None; E. Volkmann: AbbVie, 2, Boehringer-Ingelheim, 2, 5, 6, 12, Medical writing support provided by Fleishman Hillard, Bristol-Myers Squibb(BMS), 2, GlaxoSmithKleine, 2, 5, Horizon, 5, Kadmon, 5, Prometheus, 5, The National Heart, Lung and Blood Institute, 5.

To cite this abstract in AMA style:

Haussmann A, Volkmann E. Interstitial Lung Disease in MCTD: A Retrospective Cohort Study at a Large Tertiary Medical Center [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/interstitial-lung-disease-in-mctd-a-retrospective-cohort-study-at-a-large-tertiary-medical-center/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interstitial-lung-disease-in-mctd-a-retrospective-cohort-study-at-a-large-tertiary-medical-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology